Additional file 2: Primers for qPCR reactions.
miScript Primer Assays (QIAGEN®, Hilden, Germany) To evaluate the potential as biomarkers of the microRNAs profiled by microarray, we determined some criteria to use in a scoring system. Following this scoring, one point was given to a microRNA each time it meets the criteria enabling it to be defined as a potential diagnostic, prognostic and/or remission biomarker, biomarker of a disease progression, biomarker of an inherent resistance to treatment, and/or biomarker of an acquired resistance to treatment.
Additional file 3: Results of the microRNAs profiling on the three selected donors. (continued)
To evaluate the potential as biomarkers of the microRNAs profiled by microarray, we determined some criteria to use in a scoring system. Following this scoring, one point was given to a microRNA each time it meets the criteria enabling it to be defined as a potential diagnostic, prognostic and/or remission biomarker, biomarker of a disease progression, biomarker of an inherent resistance to treatment, and/or biomarker of an acquired resistance to treatment.
Additional file 10: Correlation between the microRNAs level and the blood count.
The selected microRNAs were quantified in all the samples constituting the plasma biobank and were grouped following the criteria described in the materials and methods. The relative expression of the microRNAs was evaluated by RT-qPCR and expressed using the ΔCq method using a spike-in microRNA mimic for normalization. The blood count was analyzed in patient samples and the correlation between these values and the microRNAs level was calculated by a Spearman correlation test. Our criteria to define a correlation was a P-value under 0.001 to avoid false positive and an inversely proportional relation between the ΔCq and the blood count, revealing microRNAs produced by a particular blood cell type. 
